Data Package. Upon Licensee’s written request to MPP and submission of relevant access information requested by MPP, Pfizer shall make available to Licensee, on a confidential basis, a discrete data package related to the Compound, the contents of which shall have been determined by Pfizer in its sole discretion. Prior to receiving access to the data package, Licensee may request in writing from MPP, in which event MPP shall provide to Licensee, a high-level summary of topics included in the data package, provided that such summary shall not create any obligation on the part of Pfizer to include any specific piece of information in the data package. Pfizer shall not be required to provide any other technical support or technical assistance to a Sublicensee for any reason.
Data Package. Upon Licensee's written request to MPP and submission of relevant access information requested by MPP, Shionogi shall make available to Licensee, on a confidential basis, a discrete data package related to the Compound, the contents of which shall have been determined by Shionogi in its sole discretion. Prior to receiving access to the data package, Licensee may request in writing from MPP, in which event MPP shall provide to Licensee, a high-level summary of topics included in the data package, provided that such summary shall not create any obligation on the part of Shionogi to include any specific piece of information in the data package. Shionogi shall not be required to provide any technical support or technical assistance to a Sublicensee for any reason.
Data Package. Data packages shall be prepared to support the design review presentations. The packages for the SPDR and the SCDR shall be structured to be stand-alone packages. However, detailed material (e.g., analyses provided as appendices) provided at the SPDR which has not changed at the SCDR need not be resubmitted. Detailed content shall comply with the requirements given the CDRL descriptions for SPDR and SCDR.
Data Package. For each Product model the applicable current data package shall include, but is not limited to, flyers, boilerplates technical specification lists, and other pertinent documentation intended for use by the Buyer's customer or support personnel.
Data Package. Infinity shall deliver to Novartis the following information and materials with respect to such Lead Program (collectively, the “Data Package”):
(a) Data evidencing achievement of all Lead Criteria set forth in Section 3.3.2; and
(b) The following data for the most potent compound of each Lead Series: (i) [**]; (ii) [**]; (iii) [**]; (iv) [**]and (v) [**].
Data Package. On a Reserved Target-by-Reserved Target basis, as soon as reasonably possible following completion of the activities under the applicable Reserved Target Research Plan, which shall, subject to the below, be completed by the Research Completion Deadline, the Parties shall provide the JRC with a data package containing the Development Data generated under the Reserved Target Research Plan and other information necessary for Genmab to evaluate its interest exercising an option with respect to the Reserved Target (“Reserved Target Data Package”). In addition to the Reserved Target Data Package, CureVac shall at the same time provide the LNP Technology License Documentation Package to Genmab. If the Parties cannot reasonably provide such complete Reserved Target Data Package, or if CureVac is unable to provide the LNP Technology License Documentation Package, or if certain activities in the Reserved Target Research Plan are delayed, by the Research Completion Deadline, and unless the Parties mutually agree an extension of the Research Completion Deadline and the Reservation Period (such agreement not to be unreasonably withheld if there are outstanding Development activities required under the Reserved Target Research Plan), the Reservation Period shall be extended to allow Genmab to evaluate its interest in exercising an option pursuant to Section 3.4 by the shorter of (i) [*****] after receipt by the JRC of the complete Reserved Target Data Package and LNP Technology License Documentation Package; or (ii) [*****] after the commencement of the Reservation Period where the corresponding Reserved Target Research Plan relates to a Single Antibody Product and [*****] after commencement of the Reservation Period where the corresponding Reserved Target Research Plan relates to a Cocktail Product.
Data Package. At a Party’s request during the Research Term, but in any event within [***], the other Party shall provide a data package to the requesting Party, which data package will include, to the extent available and in the Control of the other Party: all in-vitro, preclinical and toxicology data and analyses (including electronic or other reasonable access to all raw data) for such Collaboration Target and any Collaboration Compounds Directed to such Collaboration Target, to the fullest extent reasonably possible so as to assist and enable the requesting Party to make its decision on whether to exercise the Lilly Option or NextCure Option, as applicable, with respect thereto (the “Data Package”); provided that the parameters and contents required for any such Data Package shall be identified and included in each applicable Project Plan; provided, further, that, notwithstanding the foregoing, any such Data Package shall only include the data generated until the date of provision of such Data Package to the applicable Party. The Parties may modify the required contents of the Data Package, if mutually agreed. NextCure shall, during the Lilly Option Period for such Collaboration Target, as requested by Lilly, meet with Lilly to discuss such Data Package and any questions Lilly may have with respect thereto, including providing Lilly with such additional information to assist with interpretation of the Data Package as Lilly may reasonably request. Lilly shall, during the NextCure Option Period for such Collaboration Target, as requested by NextCure, meet with NextCure to discuss such Data Package and any questions NextCure may have with respect thereto, including providing NextCure with such additional information to assist with interpretation of the Data Package as NextCure may reasonably request.
Data Package. For each Company Selected Compound, as promptly as possible (and in no event later than any date for the for the delivery thereof specified in the Research Plan or as otherwise agreed by the Parties in writing), SpinCo will assemble and deliver to the Company a Data Package for such Company Selected Compound.
Data Package. Once a Collaboration Compound completes a POC Trial (and thus becomes a POC Compound), NGM shall, within [*] of such completion, provide a mutually agreed upon data package to Merck, which data package will in any event include: (i) [*]; (ii) [*]; (iii) [*]; (iv) [*]; (v) [*]; (vi) [*], in each case of (i) through (vi), inclusive, to the fullest extent reasonably possible so as to assist and enable Merck to make its decision on whether to exercise the Merck Option with respect thereto; and (vii) an executed statement affirming the representations and warranties in Sections 11.1 and 11.2 remain accurate or otherwise noting any disclosures necessary to make such representations and warranties accurate, which disclosures shall not be considered, of themselves, to be a breach of this Agreement(the “Data Package”). NGM shall, during the Option Period for such POC Compound and, as requested by Merck, meet with Merck to discuss such Data Package and any questions of Merck with respect thereto, including providing Merck with such additional information to assist with interpretation of the Data Package as Merck may reasonably request.
Data Package. (a) [***] following completion of the Planned Xxxxx 0 Xxxxx, Xxxxx 0 (X.X.) Trial and, if conducted during the Term, the ACTIV Xxxxx 0x/Xxxxx 0 Xxxxx, XXXX shall deliver the applicable Data Package to Novartis. Novartis shall promptly confirm in writing receipt of such Data Package.
(b) [***], Novartis shall have the right to request from MPAG such additional information then in the possession of or readily available to MPAG (without the need for MPAG to incur additional material external costs or additional material internal expense) as Novartis may reasonably require in order to make a scientific, legal and business evaluation of the development and marketing potential of the Product. MPAG shall also promptly notify Novartis of, and promptly provide to Novartis, all material new data relating to the Product that comes into MPAG’s possession [***].
